Show simple item record

dc.contributor.authorRomero Ben, Elena
dc.contributor.authorGoswami, Upashi
dc.contributor.authorSoto Cruz, Jackeline
dc.contributor.authorMansoori-Kermani, Amirreza
dc.contributor.authorMishra, Dhiraj
dc.contributor.authorMartín Saldaña, Sergio
dc.contributor.authorMuñoz Ugartemendia, Jone
dc.contributor.authorSosnik, Alejandro
dc.contributor.authorCalderón, Marcelo
dc.contributor.authorBeloqui Elizazu, Ana
dc.contributor.authorLarrañaga Espartero, Aitor ORCID
dc.date.accessioned2025-04-02T13:02:28Z
dc.date.available2025-04-02T13:02:28Z
dc.date.issued2025-04
dc.identifier.citationActa Biomaterialia 196 : 17-49 (2025)es_ES
dc.identifier.issn1742-7061
dc.identifier.issn1878-7568
dc.identifier.urihttp://hdl.handle.net/10810/73102
dc.description.abstractTherapeutic biomacromolecules such as genetic material, antibodies, growth factors and enzymes represent a novel therapeutic alternative for neurological diseases and disorders. In comparison to traditional therapeutics, which are mainly based on small molecular weight drugs that address the symptoms of these disorders, therapeutic biomacromolecules can reduce undesired side effects and target specific pathological pathways, thus paving the way towards personalized medicine. However, these biomacromolecules undergo degradation/denaturation processes in the physiological environment and show poor capacity to cross the blood-brain barrier (BBB). Consequently, they rarely reach the central nervous system (CNS) in their active form. Herein, we critically overview several polymeric nanocarriers that can protect and deliver therapeutic biomacromolecules across the BBB. Polymeric nanocarriers are first categorized based on their architecture (biodegradable solid nanoparticles, nanogels, dendrimers, self-assembled nanoparticles) that ultimately determines their physico-chemical properties and function. The available polymeric formulations are then thoroughly analyzed, placing particular attention on those strategies that ensure the stability of the biomacromolecules during their encapsulation process and promote their passage across the BBB by controlling their physical (e.g., mechanical properties, size, surface charge) and chemical (e.g., surface functional groups, targeting motifs) properties. Accordingly, this review gives a unique perspective on polymeric nanocarriers for the delivery of therapeutic biomacromolecules across the BBB, representing a concise, complete and easy-to-follow guide, which will be of high interest for chemists, material scientists, pharmacologists, and biologists. Besides, it also provides a critical perspective about the limited clinical translation of these systems.es_ES
dc.description.sponsorshipWe acknowledge the financial support of “Innovative Tools to Treat and Model Complex Cancer Environments” project, TheraTools (Ref. 101073404. HORIZON-MSCA-2021-DN-01 call). MC received funding of Basque Government (projects 2023333010, 2023333023, PIBA2023-1-0043), the University of the Basque Country (projects COLLAB22/05 and GIU21/033), IKERBASQUE-Basque Foundation for Science, the Ministry of Science and Innovation of the Government of Spain (grant PID2022-142739OB-I00 funded by MICIU/AEI/ 10.13039/501100011033 and by FEDER, UE; 'María de Maeztu' Programme for Center of Excellence in R&D, grant CEX2023-001303-M funded by MICIU/AEI/10.13039/501100011033). AB acknowledges the Spanish Research Agency (PID2022-142128NB-I00 and CNS2023-145416 funded by MCIN/AEI/10.13039/501100011033/ and by the "European Union NextGenerationEU/PRTR"; RYC2018-025923-I from RyC program - MCIN/AEI /10.13039/501100011033 and FSE "invierte en tu futuro"; “María de Maeztu” Programme for Center of Excellence in R&D, grant CEX2023-001303-M funded by MICIU/AEI/ 10.13039/501100011033), and IKERBASQUE-Basque Foundation for Science. AS thanks the support of the Tamara and Harry Handelsman Academic Chair. AL and JMU are thankful for funds from the Basque Government, Department of Education (IT1766-22). SMS was supported by the IKUR Strategy of the Basque Country. ERB was supported by «Investigo Programme» of the Recovery, Transformation and Resilience Plan, funded by the European Union-NextGeneration EU, with reference 2022/IKER/000006.es_ES
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.relationinfo:eu-repo/grantAgreement/EC/H2020/101073404es_ES
dc.relationinfo:eu-repo/grantAgreement/MICINN/PID2022-142739OB-I00es_ES
dc.relationinfo:eu-repo/grantAgreement/MICINU/CEX2023-001303-Mes_ES
dc.relationinfo:eu-repo/grantAgreement/MICINU/CNS2023-145416es_ES
dc.relationinfo:eu-repo/grantAgreement/MICIU/RYC2018-025923-Ies_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es/*
dc.subjectbiomacromoleculeses_ES
dc.subjectblood-brain barrier transportes_ES
dc.subjectpolymeric nanoparticleses_ES
dc.subjectneurological disorderses_ES
dc.titlePolymer-based nanocarriers to transport therapeutic biomacromolecules across the blood-brain barrieres_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.holder© 2025 The Authors. Published by Elsevier Inc. on behalf of Acta Materialia Inc. This is an open access article under the CC BY-NC-ND licensees_ES
dc.rights.holderAtribución-NoComercial-SinDerivadas 3.0 España*
dc.relation.publisherversionhttps://www.sciencedirect.com/science/article/pii/S174270612500162Xes_ES
dc.identifier.doi10.1016/j.actbio.2025.02.065
dc.contributor.funderEuropean Commission
dc.departamentoesIngeniería Minera y Metalúrgica y Ciencia de los Materialeses_ES
dc.departamentoeuMeatze eta metalurgia ingeniaritza materialen zientziaes_ES


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

© 2025 The Authors. Published by Elsevier Inc. on behalf of Acta Materialia Inc. This is an open access article under the CC BY-NC-ND license
Except where otherwise noted, this item's license is described as © 2025 The Authors. Published by Elsevier Inc. on behalf of Acta Materialia Inc. This is an open access article under the CC BY-NC-ND license